177 related articles for article (PubMed ID: 20160706)
1. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.
Evgin L; Vähä-Koskela M; Rintoul J; Falls T; Le Boeuf F; Barrett JW; Bell JC; Stanford MM
Mol Ther; 2010 May; 18(5):896-902. PubMed ID: 20160706
[TBL] [Abstract][Full Text] [Related]
2. The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses.
Mundi N; Um S; Yoo J; Rizzo G; Black M; Pinto N; Palma DA; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Virus Res; 2014 Sep; 190():53-9. PubMed ID: 25038405
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.
Echchgadda I; Chang TH; Sabbah A; Bakri I; Ikeno Y; Hubbard GB; Chatterjee B; Bose S
BMC Cancer; 2011 Jan; 11():43. PubMed ID: 21276246
[TBL] [Abstract][Full Text] [Related]
4. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
Breitbach CJ; Thorne SH; Bell JC; Kirn DH
Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365
[TBL] [Abstract][Full Text] [Related]
5. Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis.
Hu J; Wang H; Gu J; Liu X; Zhou X
Acta Biochim Biophys Sin (Shanghai); 2018 Oct; 50(10):1018-1027. PubMed ID: 30137199
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
7. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
Parato KA; Breitbach CJ; Le Boeuf F; Wang J; Storbeck C; Ilkow C; Diallo JS; Falls T; Burns J; Garcia V; Kanji F; Evgin L; Hu K; Paradis F; Knowles S; Hwang TH; Vanderhyden BC; Auer R; Kirn DH; Bell JC
Mol Ther; 2012 Apr; 20(4):749-58. PubMed ID: 22186794
[TBL] [Abstract][Full Text] [Related]
8. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.
Kirn DH; Thorne SH
Nat Rev Cancer; 2009 Jan; 9(1):64-71. PubMed ID: 19104515
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
10. A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.
Thirunavukarasu P; Sathaiah M; Gorry MC; O'Malley ME; Ravindranathan R; Austin F; Thorne SH; Guo ZS; Bartlett DL
Mol Ther; 2013 May; 21(5):1024-33. PubMed ID: 23439499
[TBL] [Abstract][Full Text] [Related]
11. Replicating poxviruses for human cancer therapy.
Kim M
J Microbiol; 2015 Apr; 53(4):209-18. PubMed ID: 25845536
[TBL] [Abstract][Full Text] [Related]
12. Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.
Cuddington BP; Mossman KL
J Virol; 2014 Jun; 88(12):6885-95. PubMed ID: 24696490
[TBL] [Abstract][Full Text] [Related]
13. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.
Thorne SH; Hwang TH; O'Gorman WE; Bartlett DL; Sei S; Kanji F; Brown C; Werier J; Cho JH; Lee DE; Wang Y; Bell J; Kirn DH
J Clin Invest; 2007 Nov; 117(11):3350-8. PubMed ID: 17965776
[TBL] [Abstract][Full Text] [Related]
14. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer.
Sathaiah M; Thirunavukkarasu P; O'Malley ME; Kavanagh MA; Ravindranathan R; Austin F; Guo ZS; Bartlett DL
Cancer Gene Ther; 2012 Mar; 19(3):192-201. PubMed ID: 22116377
[TBL] [Abstract][Full Text] [Related]
16. Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68.
Gentschev I; Donat U; Hofmann E; Weibel S; Adelfinger M; Raab V; Heisig M; Chen N; Yu YA; Stritzker J; Szalay AA
J Biomed Biotechnol; 2010; 2010():489759. PubMed ID: 20379368
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
[TBL] [Abstract][Full Text] [Related]
18. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
19. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
